Philip Clarke

Philip Clarke is a seasoned professional in the field of drug metabolism and pharmacokinetics (DMPK), currently serving as Senior Principal Scientist at BenevolentAI since November 2018, where scientific and management leadership is provided to the DMPK group. Prior experience includes significant roles at Vertex Pharmaceuticals, Evotec, Prosidion, Pfizer, and Quintiles, with responsibilities ranging from leading bioanalytical activities to managing large teams and developing innovative biomarker strategies. Philip holds a PhD in Analytical Chemistry from Sheffield Hallam University and a BSc in Chemistry from the University of Plymouth, bringing extensive expertise in bioanalysis and DMPK to various research and development projects across the pharmaceutical industry.